Contribution of different HFE genotypes to iron overload disease: a pooled analysis
- PMID: 11399207
- DOI: 10.1097/00125817-200009000-00001
Contribution of different HFE genotypes to iron overload disease: a pooled analysis
Abstract
Purpose: To determine the contribution of the C282Y and H63D mutations in the HFE gene to clinical expression of hereditary hemochromatosis.
Methods: Pooled analysis of 14 case-control studies reporting HFE genotype data, to evaluate the association of different HFE genotypes with iron overload. In addition, we used data from the pooled analysis and published data to estimate the penetrance of the C282Y/C282Y genotype.
Results: Homozygosity for the C282Y mutation carried the largest risk for iron overload (OR = 4383, 95% CI 1374 to >10,000) and accounted for the majority of hemochromatosis cases (attributable fraction (AF) = 0.73). Risks for other genotypes were much smaller: OR = 32 for genotype C282Y/H63D (95% CI 18.5 to 55.4, AF = 0.06); OR = 5.7 for H63D/H63D (95% CI 3.2 to 10.1, AF = 0.01); OR = 4.1 for C282Y heterozygosity (95% CI 2.9 to 5.8, with heterogeneity in study results, making this association uncertain); and OR = 1.6 for H63D heterozygosity (95% CI 1 to 2.6, AF = 0.03). Estimates of penetrance for the C282Y/C282Y genotype were highly sensitive to estimates of the prevalence of iron overload disease. At a prevalence of 2.5 per 1000 or less, penetrance of the C282Y/C282Y genotype is unlikely to exceed 50%. Penetrance of other HFE genotypes is much lower.
Conclusions: C282Y homozygosity confers the highest risk for iron overload but the H63D mutation is also associated with increased risk. Our data indicate a gradient of risk associated with different HFE genotypes and thus suggest the presence of other modifiers, either genetic or environmental, that contribute to the clinical expression of hemochromatosis.
Similar articles
-
Hemochromatosis genotypes and risk of iron overload--a meta-analysis.Ann Epidemiol. 2011 Jan;21(1):1-14. doi: 10.1016/j.annepidem.2010.05.013. Epub 2010 Aug 30. Ann Epidemiol. 2011. PMID: 20800508
-
Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients.Blood Cells Mol Dis. 2002 Jul-Aug;29(1):41-7. doi: 10.1006/bcmd.2002.0536. Blood Cells Mol Dis. 2002. PMID: 12482402
-
Association of HFE mutations (C282Y and H63D) with iron overload in blood donors from Mexico City.Ann Hepatol. 2007 Jan-Mar;6(1):55-60. Ann Hepatol. 2007. PMID: 17297430
-
HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology.Am J Epidemiol. 2001 Aug 1;154(3):193-206. doi: 10.1093/aje/154.3.193. Am J Epidemiol. 2001. PMID: 11479183 Review.
-
[Iron in the era of molecular biology].Pathol Biol (Paris). 1999 Nov;47(9):938-44. Pathol Biol (Paris). 1999. PMID: 10609274 Review. French.
Cited by
-
Hereditary Hemochromatosis and Iron Metabolism.EJIFCC. 2001 Jul 22;13(2):31-38. eCollection 2001 Jul. EJIFCC. 2001. PMID: 30429720 Free PMC article. No abstract available.
-
Best practice guidelines for the molecular genetic diagnosis of Type 1 (HFE-related) hereditary haemochromatosis.BMC Med Genet. 2006 Nov 29;7:81. doi: 10.1186/1471-2350-7-81. BMC Med Genet. 2006. PMID: 17134494 Free PMC article.
-
HFE gene mutations increase the risk of coronary heart disease in women.Eur J Epidemiol. 2010 Sep;25(9):643-9. doi: 10.1007/s10654-010-9489-6. Epub 2010 Jul 18. Eur J Epidemiol. 2010. PMID: 20640879 Free PMC article.
-
Evaluation of a screening program for iron overload and HFE mutations in 50,493 blood donors.Ann Hematol. 2020 Oct;99(10):2295-2301. doi: 10.1007/s00277-020-04146-8. Epub 2020 Aug 26. Ann Hematol. 2020. PMID: 32844323 Free PMC article.
-
Transient elevation of serum ferritin in a Sri Lankan with homozygosity for H63D mutation in the HFE gene: a case report.J Med Case Rep. 2020 Jul 9;14(1):93. doi: 10.1186/s13256-020-02428-3. J Med Case Rep. 2020. PMID: 32641120 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources